BioSpace has announced its NextGen class of 2026, which has attracted significant investment despite financial constraints. The class includes several biotech startups, such as City Therapeutics, which has secured a substantial series B funding. Other companies, including Stylus, Corsera, and Trace, are also making notable advancements in their respective fields, including cell therapy and treatment development.